Sanara MedTech Inc. - 8-K Filing
Sanara MedTech Inc. terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026, as part of a strategic shift to focus on soft tissue repair and bone fusion products for the surgical market. Ronald T. Nixon, the Company’s Chairman, is founder and managing partner of Catalyst, which owns more than 5% of Sanara's common stock. No fee or penalty was paid in connection with the termination. (Items: 1.02 Termination of a Material Definitive Agreement)
Tickers: $SMTI